|
R&D Systems
quantikine human elisa kits Quantikine Human Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pm25481288-64-0-4?v=R%26D+Systems Average 93 stars, based on 1 article reviews
quantikine human elisa kits - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
R&D Systems
human tfpi Human Tfpi, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pm25849335-49-2-7?v=R%26D+Systems Average 93 stars, based on 1 article reviews
human tfpi - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
tfpi Tfpi, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pm29242228-161-25-27?v=Santa+Cruz+Biotechnology Average 93 stars, based on 1 article reviews
tfpi - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
R&D Systems
tfpi Tfpi, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/10__1097_slash_mbc__0000000000000120-53-11-19?v=R%26D+Systems Average 93 stars, based on 1 article reviews
tfpi - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
OriGene
tfpi2 ![]() Tfpi2, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pmc13178667-160-12-13?v=OriGene Average 94 stars, based on 1 article reviews
tfpi2 - by Bioz Stars,
2026-08
94/100 stars
|
Buy from Supplier |
|
Cusabio
rat tfpi ![]() Rat Tfpi, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pmc04796743-68-3-11?v=Cusabio Average 90 stars, based on 1 article reviews
rat tfpi - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
Cusabio
elisa kits ![]() Elisa Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pm39757570-59-0-7?v=Cusabio Average 93 stars, based on 1 article reviews
elisa kits - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
mouse anti tfpi2 b7 ![]() Mouse Anti Tfpi2 B7, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pmc03947444-97-79-82?v=Santa+Cruz+Biotechnology Average 93 stars, based on 1 article reviews
mouse anti tfpi2 b7 - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
Novus Biologicals
anti tfpi ![]() Anti Tfpi, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/10__1160_slash_th16___03___0218-90-24-27?v=Novus+Biologicals Average 90 stars, based on 1 article reviews
anti tfpi - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
R&D Systems
anti human tf goat polyclonal antibody ![]() Anti Human Tf Goat Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pmc05892427-60-10-15?v=R%26D+Systems Average 90 stars, based on 1 article reviews
anti human tf goat polyclonal antibody - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
R&D Systems
tfpi polyclonal antibodies ![]() Tfpi Polyclonal Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/10__1097_slash_shk__0000000000001120-39-4-10?v=R%26D+Systems Average 92 stars, based on 1 article reviews
tfpi polyclonal antibodies - by Bioz Stars,
2026-08
92/100 stars
|
Buy from Supplier |
|
R&D Systems
goat anti mouse tf polyclonal antibody ![]() Goat Anti Mouse Tf Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tfpi/pm22327225-40-25-29?v=R%26D+Systems Average 92 stars, based on 1 article reviews
goat anti mouse tf polyclonal antibody - by Bioz Stars,
2026-08
92/100 stars
|
Buy from Supplier |
Image Search Results
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A ) Strategy for identification of 4 key genes encoding secreted proteins that are downregulated (fold change > 2) by CLOCK depletion in GSC272 with inducible CLOCK shRNA (ish CLOCK ) versus inducible shRNA control (ishC), and by BMAL1 depletion in T387 and T3565 with BMAL1 shRNA (sh BMAL1 ) versus shRNA control (shC). ( B ) Heat map shows the expression of TFPI2 , COL8A1 , LRRC17, and PLA2R1 in GSC272, T387, and T3565 harboring ishC versus ish CLOCK and shC versus sh BMAL1 . Red and blue indicate higher and lower expression, respectively. ( C and D ) ChIP-seq data analysis shows the heatmap ( C ) and quantification ( D ) of BMAL1-enriched profiles at TFPI2 , COL8A1 , LRRC17, and PLA2R1 promotors in GSCs (T387 and T3565) and NSCs (ENSA and hNP1). n = 4. ( E ) ChIP-seq data analysis shows BMAL1-enriched profiles at the TFPI2 promotor in NSC #1 and #2 (ENSA and hNP1) and GSC #1 and #2 (T387 and T3565). ( F and G ) RT-qPCR for CLOCK and TFPI2 in control, CLOCK-depleted ( F , n = 4), and BMAL1-depleted ( G , n = 3) GSC272. ( H ) RT-qPCR for TFPI2 in GSC20 and GSC272 treated with or without SR9009 (5 μmol/L). n = 3 independent samples. ( I and J ) RT-qPCR for CLOCK and TFPI2 in GSC17 ( I ) or GSC23 ( J ) harboring CLOCK overexpression (OE). n = 3. ( K and L ) Immunoblots for CLOCK, BMAL1, and TFPI2 in GSC272 harboring shC and sh CLOCK ( K ), or shC and sh BMAL1 ( L ). ( M ) Immunoblots for CLOCK and TFPI2 in GSC20 and GSC272 treated with or without SR9009 (1 and 5 μmol/L). ( N and O ) Immunoblots for CLOCK, BMAL1, and TFPI2 in GSC17 ( N ) or GSC23 ( O ) harboring CLOCK OE. Data from multiple replicates are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, Student’s t test ( D and F – J ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: shRNA, Control, Expressing, ChIP-sequencing, Quantitative RT-PCR, Over Expression, Western Blot
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A – D ) Immunoblots ( A and B ) and RT-qPCR ( C and D , n = 3) for CD133 ( PROM1 ) and SOX2 in GSC272 harboring shRNA control (shC), CLOCK shRNA (sh CLOCK , A ), or sh BMAL1 ( B ) in the presence or absence of TFPI2 overexpression (OE). n = 3. ( E and F ) In vitro limiting dilution assays in GSC272 harboring shC, sh CLOCK ( E ), or sh BMAL1 ( F ) in the presence or absence of TFPI2 OE. ( G – I ) Representative images ( G ) and quantification of relative tumorsphere number ( H ) and size ( I ) of GSC272 expressing shC, sh CLOCK, or sh BMAL1 in the presence or absence of TFPI2 OE. Scale bar: 200 μm. n = 8. ( J – M ) Representative images and quantification of proliferation in GSC272 harboring shC, sh CLOCK ( J and K ), and sh BMAL1 ( L and M ) with or without TFPI2 OE. n = 3. ( N – Q ) Immunoblots ( N and O ) and RT-qPCR ( P and Q , n = 3) for CD133 ( PROM1 ) and SOX2 in GSC17 and GSC23 harboring Control or CLOCK OE with or without sh TFPI2 . ( R and S ) In vitro limiting dilution assays in GSC17 ( R ) and GSC23 ( S ) expressing Control or CLOCK OE with or without sh TFPI2 . ( T and U ) Representative images ( T ) and quantification of relative tumorsphere number ( U ) of GSC17 or GSC23 harboring CLOCK OE in the presence or absence of sh TFPI2 . Scale bar: 200 μm. n = 8. ( V – Y ) Representative images and quantification of proliferation in GSC17 ( V and W ) and GSC23 ( X and Y ) harboring CLOCK OE in the presence or absence of sh TFPI2 . n = 3. Data from multiple replicates are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, 1-way ANOVA test ( C , D , H , I , K , M , P , Q , U , W , and Y ), 2-way ANOVA test ( E , F , R , and S ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: Western Blot, Quantitative RT-PCR, shRNA, Control, Over Expression, In Vitro, Expressing
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A ) Amplification pattern TFPI2 and CLOCK in TCGA GBM patient tumors from indicated datasets. ( B ) High-resolution uniform manifold approximation and projection (UMAP) showing expression of CLOCK and TFPI2 in GSCs (the population of cells are highlighted in circle) of GBM patient tumors based on scRNA-Seq data ( GSE182109 ). ( C ) Relationship between CLOCK and TFPI2 expression in GSCs from GBM patient tumors based on scRNA-Seq data ( GSE182109 ). R and P values are shown. Pearson’s correlation test. ( D ) In vitro limiting dilution assays in GSC272 harboring shRNA control (shC) and TFPI2 shRNA (sh TFPI2 ) treated with or without SR9009 (5 μM). ( E – G ) Representative images ( E ) and quantification of relative tumorsphere number ( F ) and size ( G ) of GSC272 harboring shC and sh TFPI2 and treated with or without SR9009 (5 μM). Scale bar: 200 μm. n = 8. ( H ) Survival curves of nude mice implanted with 2 × 10 5 shC and sh TFPI2 GSC272. Mice were treated with SR9009 (100 mg/kg, i.p., daily) for 10 days beginning at day 7 after orthotopic injection ( n = 8 mice per group). ( I – L ) Representative images and quantification of IHC staining for SOX2 ( I and J ) and CD133 ( K and L ) in shC and sh TFPI2 GSC272 tumors from mice treated with or without SR9009. Scale bar: 100 μm. n = 7. Data from multiple replicates are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, 1-way ANOVA test ( F , G , J , and L ), 2-way ANOVA test ( D ), log-rank test ( H ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: Amplification, Expressing, In Vitro, shRNA, Control, Injection, Immunohistochemistry
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A – D ) RT-qPCR ( A and B , n = 3) and immunoblots ( C and D ) for TFPI2, CLOCK, and BMAL1 in GSC17 and GSC23 harboring control or TFPI2 overexpression (OE). ( E ) RT-qPCR ( E , n = 3) and immunoblots ( F ) for TFPI2, CLOCK, and BMAL1 in GSC272 harboring shRNA control (shC) or TFPI2 shRNA (sh TFPI2 ). ( G and H ) Immunoblots for CD133 and SOX2 in GSC17 ( G ) and GSC23 ( H ) harboring control or TFPI2 OE and treated with or without SR9009 (5 μM). ( I ) In vitro limiting dilution assays in GSC17 harboring control or TFPI2 OE and treated with or without SR9009 (5 μM). ( J – L ) Representative images ( J ) and quantification of relative tumorsphere number ( K ) and size ( L ) of GSC17 harboring control or TFPI2 OE treated with or without SR9009 (5 μM). Scale bar: 200 μm. n = 8. ( M ) In vitro limiting dilution assays in GSC23 harboring control or TFPI2 OE and treated with or without SR9009 (5 μM). ( N – P ) Representative images ( N ) and quantification of relative tumorsphere number ( O ) and size ( P ) of GSC23 harboring control or TFPI2 OE treated with or without SR9009 (5 μM). Scale bar: 200 μm. n = 8. ( Q ) Survival curves of nude mice implanted with 2 × 10 5 Control and TFPI2 OE GSC23 and treated with SR9009 (100 mg/kg, i.p., daily) for 10 days beginning at day 7 (n = 8 mice per group). ( R – U ) Representative images and quantification of IHC staining for SOX2 ( R and S ) and CD133 ( T and U ) in Control and TFPI2 OE GSC23 tumors from mice treated with or without SR9009. Scale bar: 100 μm. n = 7. Data from multiple replicates are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, 1-way ANOVA test ( A , B , E , K , L , O , P , S , and U ), 2-way ANOVA test ( I and M ), log-rank test ( Q ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: Quantitative RT-PCR, Western Blot, Control, Over Expression, shRNA, In Vitro, Immunohistochemistry
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A ) GSEA analysis shows the top 10 enriched hallmark pathways in shRNA control (shC) GSC272 compared with TFPI2 shRNA (sh TFPI2 ) GSC272. Blue bars indicate the top 2 enriched signatures ( FDR < 0.25). ( B and C ) Immunoblots for HIF-1α, P-P65, and P65 in cell lysates of GSC17 ( B ) and GSC23 ( C ) harboring control and TFPI2 overexpression (OE). ( D ) Immunoblots for HIF-1α, P-P6,5 and P65 in cell lysates of shC and sh TFPI2 GSC272. ( E and F ) Immunoblots for HIF-1α, P-P65, and P65 in cell lysates of GSC17 ( E ) and GSC23 ( F ) harboring control and TFPI2 OE treated with or without HIF-1α inhibitor ACF (2 μM). ( G and H ) Quantification of p65 ChIP-PCR in the CLOCK promoter ( G ) and BMAL1 promoter ( H ) of GSC272. IgG was used as Control. n = 3. ( I and J ) RT-qPCR for CLOCK and BMAL1 in GSC17 ( I ) and GSC23 ( J ) harboring TFPI2 OE treated with or without ACF. n = 3. ( K and L ) RT-qPCR for CLOCK and BMAL1 in GSC17 ( K ) and GSC23 ( L ) harboring control or TFPI2 OE treated with or without P65 inhibitor SC75741. n = 3. ( M and N ) Immunoblots for CLOCK and BMAL1 in cell lysates of control and TFPI2 OE GSC17 ( M ) or GSC23 ( N ) treated with or without ACF. ( O and P ) Immunoblots for CLOCK and BMAL1 in cell lysates of control and TFPI2 OE GSC17 ( O ) or GSC23 ( P ) treated with or without SC75741. Data from multiple replicates are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, Student’s t test ( G and H ), 1-way ANOVA test ( I – L ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: shRNA, Control, Western Blot, Over Expression, Quantitative RT-PCR
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A and B ) Immunoblots for CD133 and SOX2 in cell lysates of GSC17 ( A ) and GSC23 ( B ) harboring control or TFPI2 overexpression (OE) and treated with or without HIF-1α inhibitor ACF (2 μM). ( C and D ) Immunoblots for CD133 and SOX2 in cell lysates of control and TFPI2 -OE GSC17 ( C ) and GSC23 ( D ) treated with or without P65 inhibitor SC75741 (5 μM). ( E ) In vitro limiting dilution assays in control and TFPI2 -OE GSC17 treated with or without ACF (2 μM) or SC75741 (5 μM). ( F – H ) Representative images ( F ) and quantification of relative tumorsphere number ( G ) and size ( H ) of control and TFPI2 -OE GSC17 treated with or without ACF or SC75741. Scale bar: 200 μm. n = 8. ( I ) In vitro limiting dilution assays in control and TFPI2 -OE GSC23 treated with or without ACF (2 μM) or SC75741 (5 μM). ( J – L ) Representative images ( J ) and quantification of relative tumorsphere number ( K ) and size ( L ) of control and TFPI2 -OE GSC23 treated with or without ACF or SC75741. Scale bar: 200 μm. n = 8. ( M – P ) Representative and quantification of proliferation in GSC17 ( M and N ) and GSC23 ( O and P ) harboring control or TFPI2 OE treated with or without ACF (2 μM) or SC75741 (5 μM). n = 3. Data from multiple replicates are presented as mean ± SD. ** P < 0.01, *** P < 0.001, 1-way ANOVA test ( G , H , K , L , N , and P ), 2-way ANOVA test ( E and I ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: Western Blot, Control, Over Expression, In Vitro
Journal: The Journal of Clinical Investigation
Article Title: Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
doi: 10.1172/JCI199056
Figure Lengend Snippet: ( A ) Schematic diagram depicting the positive feedback loop between TFPI2 and the CLOCK-BMAL1 complex in GSCs and the strategy of dual targeting their downstream signaling pathways to block GSC self renewal. ( B ) Survival curves of nude mice implanted with 2 × 10 5 GSC272 and treated with LDHA inhibitor Stiripentol (150 mg/kg, i.p., every other day), JNK inhibitor JNK-IN-8 (30 mg/kg, i.p., daily), STAT3 inhibitor WP1066 (30 mg/kg, i.p., daily), or Stiripentol in combination with JNK-IN-8 or WP1066 for 2 weeks beginning at day 7. n = 8 mice per group. ( C – F ) Representative images and quantification of IHC staining for SOX2 ( C and D ) and CD133 ( E and F ) in GSC272 tumors from mice with indicated treatments. Scale bar: 100 μm. n = 4. ( G and H ) Representative images ( G ) and quantification ( H ) of flow cytometry for the percentage of CD45 low CD11b + TMEM119 + CD206 + microglia (out of CD45 low CD11b + TMEM119 + microglia) in tumors from 005 GSC-bearing mice with indicated treatments. n = 3. ( I and J ) Representative images ( I ) and quantification ( J ) of flow cytometry for the percentage of CD45 + CD3 + CD8 + IFNγ + T cells (out of CD45 + CD3 + CD8 + T cells) in tumors from 005 GSC-bearing mice with indicated treatments. n = 3. ( K ) Survival curves of C57BL/6J mice implanted with 2 × 10 5 005 GSCs and treated with Stiripentol, JNK-IN-8, or WP1066, and Stiripentol in combination with JNK-IN-8 or WP1066 for 2 weeks beginning at day 7, and with anti-PD1 (10 mg/kg, i.p.) treatment on days 11, 14, and 17. n = 8 mice per group. Data from multiple replicates are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, 1-way ANOVA test ( D , F , H , and J ), log-rank test ( B and K ).
Article Snippet: Plasmids of human Tagged ORF Clone of CLOCK (Origene, # RC221408), and
Techniques: Protein-Protein interactions, Blocking Assay, Immunohistochemistry, Flow Cytometry
Journal: Journal of thrombosis and haemostasis : JTH
Article Title: Tissue factor Deficiency Increases Alveolar Hemorrhage and Death in Influenza A Infected Mice
doi: 10.1111/jth.13307
Figure Lengend Snippet: We analyzed TF antigen expression in the lungs of uninfected (B, E) and infected (7 dpi) wild-type mice (C, F), and infected TFΔEp mice (G–I) by immunohistochemistry. Tissue sections were incubated with (B, C, E, F–I) or without (A and D) a goat anti-mouse TF polyclonal antibody. The black arrows indicate TF expression in the epithelium of bronchi (Bc). The arrowheads indicate TF staining in adventitial cells of blood vessels (Bv). The white arrow indicates TF expression in adventitial cells surrounding a bronchiole. Original magnification x200. Scale bar is 100 µm.
Article Snippet: Then, slides were incubated overnight at 4°C with 1 μg/mL
Techniques: Expressing, Infection, Immunohistochemistry, Incubation, Staining
Journal: Shock
Article Title: Knockdown of TFPI-Anchored Endothelial Cells Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via NF-κB Signaling Pathway
doi: 10.1097/shk.0000000000001120
Figure Lengend Snippet: Figure 2.Coagulative function and TFPI concentration in TFPI cKO mice with ALI . WT
Article Snippet: Goat anti-mouse ACE2 and
Techniques: Concentration Assay
Journal: Shock
Article Title: Knockdown of TFPI-Anchored Endothelial Cells Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via NF-κB Signaling Pathway
doi: 10.1097/shk.0000000000001120
Figure Lengend Snippet: Figure3.Endothelial TFPI deletion exacerbated lung pathological changes in LPS-induced
Article Snippet: Goat anti-mouse ACE2 and
Techniques:
Journal: Shock
Article Title: Knockdown of TFPI-Anchored Endothelial Cells Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via NF-κB Signaling Pathway
doi: 10.1097/shk.0000000000001120
Figure Lengend Snippet: Figure4. Endothelial TFPI deletion increased vascular permeability in acute lung injury.(A)
Article Snippet: Goat anti-mouse ACE2 and
Techniques: Permeability
Journal: Shock
Article Title: Knockdown of TFPI-Anchored Endothelial Cells Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via NF-κB Signaling Pathway
doi: 10.1097/shk.0000000000001120
Figure Lengend Snippet: Figure5. Accumulation of inflammatory cells and lung inflammatory response were enhanced in TFPIcKO mice following ALI. To confirm that the inflammatory response was aggravated in TFPI cKO mice compared with WT mice, we measured cell number and cytokines
Article Snippet: Goat anti-mouse ACE2 and
Techniques:
Journal: Shock
Article Title: Knockdown of TFPI-Anchored Endothelial Cells Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via NF-κB Signaling Pathway
doi: 10.1097/shk.0000000000001120
Figure Lengend Snippet: Figure6. Endothelial-specific disruption of TFPI destroyed endothelial gap by activation of
Article Snippet: Goat anti-mouse ACE2 and
Techniques: Disruption, Activation Assay